TwitterLinkedInFacebook Instagram
United States



OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries DNA Genotek, Diversigen and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and Hepatitis C (HCV) on the OraQuick® platform; sample self-collection and stabilization products for molecular applications; and oral fluid laboratory tests for detecting various drugs of abuse.

OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers.

The Company is bringing its expertise to the COVID-19 battle with a rapid antigen self-test and an oral fluid antibody test under development. In addition, its saliva collection devices are being used for the collection, both in at home and professional settings, and transport of samples for COVID-19 molecular testing.

Stock Chart

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
BETHLEHEM, Pa., Nov. 19, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will participate in a